Please ensure Javascript is enabled for purposes of website accessibility

2 Top Pharma Stocks to Buy in August

By Zhiyuan Sun - Aug 16, 2020 at 10:47AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Here's why these recession-proof stocks are great buy-and-hold opportunities for the long term.

During good times, pharma stocks are often great buys thanks to their steady cash flow, high-profit margins, dedication to research and development, and market exclusivity from drug patents. In a global pandemic, however, pharma companies become even better buys, because of the essential nature of their business.

Steady demand for prescription drugs is why investors look to the sector for stocks that are recession-proof and COVID-19-proof. Let's take a look at two stocks that fit this category and why you should consider holding them for the long term.

Group of scientists working at the laboratory.

Image Source: Getty Images.

A large-cap pharma that's growing in all directions

In Q2 2020, sales of Regeneron Pharmaceuticals' (REGN 0.77%) widely popular eye injection, Eylea, amounted to $1.8 billion. The drug treats a variety of diseases in the retina, and demand is approaching pre-COVID-19 levels.

While Eylea rebounds, the rest of the company's portfolio has been expanding. Sales of Dupixent, an anti-inflammatory drug, increased by 70% year over year to nearly $1 billion during the quarter. The drug is 70% effective at relieving symptoms of specific allergies.

The company's skin cancer therapy, Libtayo, has also been on a tear, bringing in quarterly revenues of $80 million. Regeneron is seeking approval with the U.S. Food and Drug Administration (FDA) to expand Libtayo's label to treat various types of lung and skin cancer. The drug is three times more effective than other standard-of-care drugs at treating certain types of cancer, and has a $25 billion market opportunity.

Currently, Regeneron has about $5.7 billion in cash and investments and $1.5 billion in liabilities from debt financing, making its financial situation superb. In fact, the company recently bought out Sanofi's entire stake for $5 billion, putting more future net income into Regeneron shareholders' hands. Investors should feel confident about the company's future potential as it reinvests more than $2 billion annually into research and development programs to keep its momentum going.

And in addition to Regeneron, I think there's another company in the sector that investors will not want to miss.

Family doctor giving to patient dropper jar of cannabis concentrate oil during consultation.

Image Source: Getty Images.

Don't miss out on this cannabinoid drug company

Next up, we have a company that's revolutionizing the way to treat seizures. The drug in play is Epidiolex, which is manufactured by GW Pharmaceuticals (GWPH) and is the first FDA-approved drug that derives its active pharmaceutical ingredient from marijuana.

Epidiolex can treat two rare forms of epilepsy, with clinical studies showing up to a 48% reduction in the number of seizures. Recently, the drug has also received regulatory label expansion to treat tuberous sclerosis, a disease causing tumors that affects 50,000 patients in the U.S. alone.

If three indications weren't enough, the active ingredient used in Epidiolex is also under investigation for the treatment of multiple sclerosis and post-traumatic stress disorder. The company expects various phases 2/3 clinical studies for these conditions to commence in the first half of next year.

The good news doesn't stop from here. Epidiolex is now approved to treat its indications in Europe, as well. In Q2 2020, sales of Epidiolex outside the U.S. amounted to $17 million. The drug generated $121.3 million in revenue for GW Pharmaceuticals in the quarter, representing 68.4% year-over-year growth, compared with Q1 2019.

While its sales grew, the company's net losses narrowed. As of June 30, operating cash use per quarter was $34.3 million, a huge decrease from the $89.9 million it spent in the same period last year. The company has no debt and over $477 million in cash on its balance sheet.

Furthermore, the vast majority of patents for Epidiolex do not expire until 2035, giving the company about 15 years to capture the global anti-seizure market before generic competition enters. The company fully expects it can grow Epidiolex into a blockbuster brand. Hence, I think GW Pharmaceuticals is a fantastic growth stock to add to investors' portfolios.

Zhiyuan Sun has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$628.71 (0.77%) $4.81
GW Pharmaceuticals plc Stock Quote
GW Pharmaceuticals plc
GWPH
Sanofi Stock Quote
Sanofi
SNY
$44.37 (2.19%) $0.95

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.